The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
14-Nov-16
$346 million
Target:
Etrion Corporation's Italian solar photovoltaic platform
Acquiror:
Ultor S.p.A.
Advised Etrion Corporation, a solar independent power producer and developer, on the sale of its 60MW Italian solar photovoltaic platform to Ultor S.p.A. (a joint venture owned equally by Enel Green Power S.p.A. and F2i Fondi Italiani per le infrastrutture) for an Enterprise Value of €323mm
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$32.0 billion
Target:
Texas Competitive Electric Holdings and its subsidiaries
Advised Texas Competitive Electric Holdings, Texas’ largest power generator and competitive retail electricity provider, and its subsidiaries at the direction of its independent director in connection with its and Energy Future Holdings’ Chapter 11 proceedings
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
26-May-16
$500 million
Target:
Apex International Energy Management LLC
Advised Apex International Energy Management, a newly formed oil and gas venture focused on the Middle East and North Africa regions, in the private equity fund-raising process with multiple energy-focused financial sponsors, ultimately resulting in an initial $500 million capital commitment from Warburg Pincus.
04-May-16
$NA
Target:
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Acquiror:
Ligand Pharmaceuticals
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
22-Apr-16
$NA
Target:
Elavon do Brasil
Acquiror:
Stone Pagamentos
Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.
19-Apr-16
$NA
Target:
Total Care Medicaid Plan
Acquiror:
Molina Healthcare, Inc.
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
26-Feb-16
$NA
Target:
Policard
Acquiror:
Groupe Up
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
02-Feb-16
$314 million
Target:
11 Private Equity Fund Positions Managed by NBGI Private Equity and Team’s Spinout
Acquiror:
Deutsche Bank Private Equity and Goldman Sachs Asset Management
Advised the National Bank of Greece SA, the leading bank in Greece by deposits and total assets, on the disposal of 100% of its interests in eleven funds managed by NBGI Private Equity. The management responsibility of the funds and underlying investments will continue to be performed by the current management team along with other persons appointed by the buyers, under a new management vehicle created expressly for this purpose
21-Dec-15
$NA
Target:
Antin Solar Investments
Acquiror:
Quercus Investment Partners / Swiss Life Asset Management
Advised Antin Infrastructure Partners on its sale of Antin Solar Investments, a leading Italian solar platform, to a consortium of investors comprised of Swiss Life Asset Management and Quercus Investment Partners
15-Dec-15
$4.3 billion
Target:
Heartland Payment Systems, Inc.
Acquiror:
Global Payments Inc.
Advised Heartland Payment Systems, Inc., one of the nation’s largest payment companies, on its sale to Global Payments Inc., a leading worldwide provider of payment technology services
07-Dec-15
$755 million
Target:
Stork
Acquiror:
Fluor Corporation
Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments